Rapport Therapeutics, Inc. Common StockRAPPNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank18
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Latest
-40.35%
↓ 99% vs avg
Percentile
P18
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
-20.23%
Historical baseline
PeriodValue
Q4 2025-40.35%
Q3 202529.86%
Q2 2025-22.23%
Q1 2025-39.91%
Q4 202411.37%
Q3 20244.41%
Q2 20247.32%
Q1 2024-58.44%
Q4 2023-115.38%
Q3 202318.09%
Q2 2023-37.49%
Q1 20230.00%